Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition.
Though clinicians can predict which patients are at risk for developing metastases, traditional therapies often prove ineffective and metastatic disease is the primary cause of cancer patient death; therefore, there is a need to develop anti-metastatic therapies that can be administered over long du...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3771884?pdf=render |
| _version_ | 1818404768921419776 |
|---|---|
| author | Zhen Yang Anapatricia Garcia Songli Xu Doris R Powell Paula M Vertino Shivendra Singh Adam I Marcus |
| author_facet | Zhen Yang Anapatricia Garcia Songli Xu Doris R Powell Paula M Vertino Shivendra Singh Adam I Marcus |
| author_sort | Zhen Yang |
| collection | DOAJ |
| description | Though clinicians can predict which patients are at risk for developing metastases, traditional therapies often prove ineffective and metastatic disease is the primary cause of cancer patient death; therefore, there is a need to develop anti-metastatic therapies that can be administered over long durations to specifically inhibit the motility of cancer cells. Withaniasomnifera root extracts (WRE) have anti-proliferative activity and the active component, Withaferin A, inhibits the pro-metastatic protein, vimentin. Vimentin is an intermediate filament protein and is part of the epithelial to mesenchymal transition (EMT) program to promote metastasis. Here, we determined whether WRE standardized to Withaferin A (sWRE) possesses anti-metastatic activity and whether it inhibits cancer motility via inhibition of vimentin and the EMT program. Several formulations of sWRE were created to enrich for Withaferin A and a stock solution of sWRE in EtOH could recover over 90% of the Withaferin A found in the original extract powder. This sWRE formulation inhibited breast cancer cell motility and invasion at concentrations less than 1µM while having negligible cytotoxicity at this dose. sWRE treatment disrupted vimentin morphology in cell lines, confirming its vimentin inhibitory activity. To determine if sWRE inhibited EMT, TGF-β was used to induce EMT in MCF10A human mammary epithelial cells. In this case, sWRE prevented EMT induction and inhibited 3-D spheroid invasion. These studies were taken into a human xenograft and mouse mammary carcinoma model. In both models, sWRE and Withaferin A showed dose-dependent inhibition of tumor growth and metastatic lung nodule formation with minimal systemic toxicity. Taken together, these data support the hypothesis that low concentrations of sWRE inhibit cancer metastasis potentially through EMT inhibition. Moreover, these doses of sWRE have nearly no toxicity in normal mouse organs, suggesting the potential for clinical use of orally administered WRE capsules. |
| first_indexed | 2024-12-14T08:45:24Z |
| format | Article |
| id | doaj.art-a7742008364146ddb1b746a5a5b08b69 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T08:45:24Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a7742008364146ddb1b746a5a5b08b692022-12-21T23:09:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0189e7506910.1371/journal.pone.0075069Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition.Zhen YangAnapatricia GarciaSongli XuDoris R PowellPaula M VertinoShivendra SinghAdam I MarcusThough clinicians can predict which patients are at risk for developing metastases, traditional therapies often prove ineffective and metastatic disease is the primary cause of cancer patient death; therefore, there is a need to develop anti-metastatic therapies that can be administered over long durations to specifically inhibit the motility of cancer cells. Withaniasomnifera root extracts (WRE) have anti-proliferative activity and the active component, Withaferin A, inhibits the pro-metastatic protein, vimentin. Vimentin is an intermediate filament protein and is part of the epithelial to mesenchymal transition (EMT) program to promote metastasis. Here, we determined whether WRE standardized to Withaferin A (sWRE) possesses anti-metastatic activity and whether it inhibits cancer motility via inhibition of vimentin and the EMT program. Several formulations of sWRE were created to enrich for Withaferin A and a stock solution of sWRE in EtOH could recover over 90% of the Withaferin A found in the original extract powder. This sWRE formulation inhibited breast cancer cell motility and invasion at concentrations less than 1µM while having negligible cytotoxicity at this dose. sWRE treatment disrupted vimentin morphology in cell lines, confirming its vimentin inhibitory activity. To determine if sWRE inhibited EMT, TGF-β was used to induce EMT in MCF10A human mammary epithelial cells. In this case, sWRE prevented EMT induction and inhibited 3-D spheroid invasion. These studies were taken into a human xenograft and mouse mammary carcinoma model. In both models, sWRE and Withaferin A showed dose-dependent inhibition of tumor growth and metastatic lung nodule formation with minimal systemic toxicity. Taken together, these data support the hypothesis that low concentrations of sWRE inhibit cancer metastasis potentially through EMT inhibition. Moreover, these doses of sWRE have nearly no toxicity in normal mouse organs, suggesting the potential for clinical use of orally administered WRE capsules.http://europepmc.org/articles/PMC3771884?pdf=render |
| spellingShingle | Zhen Yang Anapatricia Garcia Songli Xu Doris R Powell Paula M Vertino Shivendra Singh Adam I Marcus Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition. PLoS ONE |
| title | Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition. |
| title_full | Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition. |
| title_fullStr | Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition. |
| title_full_unstemmed | Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition. |
| title_short | Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition. |
| title_sort | withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition |
| url | http://europepmc.org/articles/PMC3771884?pdf=render |
| work_keys_str_mv | AT zhenyang withaniasomniferarootextractinhibitsmammarycancermetastasisandepithelialtomesenchymaltransition AT anapatriciagarcia withaniasomniferarootextractinhibitsmammarycancermetastasisandepithelialtomesenchymaltransition AT songlixu withaniasomniferarootextractinhibitsmammarycancermetastasisandepithelialtomesenchymaltransition AT dorisrpowell withaniasomniferarootextractinhibitsmammarycancermetastasisandepithelialtomesenchymaltransition AT paulamvertino withaniasomniferarootextractinhibitsmammarycancermetastasisandepithelialtomesenchymaltransition AT shivendrasingh withaniasomniferarootextractinhibitsmammarycancermetastasisandepithelialtomesenchymaltransition AT adamimarcus withaniasomniferarootextractinhibitsmammarycancermetastasisandepithelialtomesenchymaltransition |